Sam-A Pharm

삼아제약 · 009300

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$62.7M (₩86.6B)

Overview

Sam-A Pharm makes prescription and over-the-counter medicines, including respiratory treatments, antibiotics, skin-care drugs, digestive aids, and fever-and-pain relievers, for patients in South Korea.

It supplies these products to hospitals, clinics, and wholesale distributors through offices across Seoul and regional cities. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company earns the large majority of its revenue from its respiratory medicine line.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$56.4M
▼ −18.6% YoY
Operating profit · FY2025
US$8M
▼ −55.1% YoY
Net income · FY2025
US$9.4M
▼ −41.4% YoY

Revenue

  • FY2023US$70.4M
  • FY2024US$69.3M
  • FY2025US$56.4M

Operating profit

  • FY2023US$17M
  • FY2024US$17.7M
  • FY2025US$8M

Net income

  • FY2023US$15.5M
  • FY2024US$16M
  • FY2025US$9.4M

Key ratios (FY2025)

ROE
5.7%
Debt/Eq
8.3%
Op. margin
14.1%
Net margin
16.6%
Rev. YoY
▼ −18.6%

Why it matters

The company operates a dedicated manufacturing plant certified under Korea's Good Manufacturing Practice standard, capable of producing solid-dose, liquid, topical, and health-supplement products.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.